Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOMEK: Mirdametinib + Chemoimmunotherapy in First-Line Metastatic Non-Squamous NSCLC
NCT05937906Phase 2Recruiting
- Sponsor
- Centre Georges-François Leclerc
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in non-small cell lung cancer (NSCLC), sponsored by Centre Georges-François Leclerc. Started Jul 2026; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05937906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937906.